super(123)I-2 beta -carbomethoxy-3 beta -(4-iodoph enyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography and super(123)I-metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with lewy bodies from other dementias: A comparative study

Objective To compare the diagnostic value of striatal super(123)I-2 beta -carbomethoxy-3 beta -(4-iod ophenyl)-N-(3-fluoropropyl) nortropane ( super(123)I-FP-CIT) single photon emission computed tomography (SPECT) and super(123)I-metaiodobenzylguanidine ( super(123)I-MIBG) myocardial scintigraphy in...

Full description

Saved in:
Bibliographic Details
Published in:Annals of neurology Vol. 80; no. 3; pp. 368 - 378
Main Authors: Tiraboschi, Pietro, Corso, Angelo, Guerra, Ugo Paolo, Nobili, Flavio, Piccardo, Arnoldo, Calcagni, Maria Lucia, Volterrani, Duccio, Cecchin, Diego, Tettamanti, Mauro, Antelmi, Luigi, Vidale, Simone, Sacco, Leonardo, Merello, Maria, Stefanini, Stefano, Micheli, Anna, Vai, Paola, Capitanio, Selene, Gabanelli, Sara Vincenzina, Riva, Riccardo, Pinto, Patrizia, Biffi, Ave Maria, Muscio, Cristina
Format: Journal Article
Language:English
Published: 01-09-2016
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To compare the diagnostic value of striatal super(123)I-2 beta -carbomethoxy-3 beta -(4-iod ophenyl)-N-(3-fluoropropyl) nortropane ( super(123)I-FP-CIT) single photon emission computed tomography (SPECT) and super(123)I-metaiodobenzylguanidine ( super(123)I-MIBG) myocardial scintigraphy in differentiating dementia with Lewy bodies (DLB) from other dementia types. Methods This prospective longitudinal study included 30 patients with a clinical diagnosis of DLB and 29 patients with non-DLB dementia (Alzheimer disease, n=16; behavioral variant frontotemporal dementia, n=13). All patients underwent super(123)I-FP-CIT SPECT and super(123)I-MIBG myocardial scintigraphy within a few weeks of clinical diagnosis. All diagnoses at each center were agreed upon by the local clinician and an independent expert, both unaware of imaging data, and re-evaluated after 12 months. Each image was visually classified as either normal or abnormal by 3 independent nuclear physicians blinded to patients' clinical data. Results Overall, sensitivity and specificity to DLB were respectively 93% and 100% for super(123)I-MIBG myocardial scintigraphy, and 90% and 76% for super(123)I-FP-CIT SPECT. Lower specificity of striatal compared to myocardial imaging was due to decreased super(123)I-FP-CIT uptake in 7 non-DLB subjects (3 with concomitant parkinsonism) who had normal super(123)I-MIBG myocardial uptake. Notably, in our non-DLB group, myocardial imaging gave no false-positive readings even in those subjects (n=7) with concurrent medical illnesses (diabetes and/or heart disease) supposed to potentially interfere with super(123)I-MIBG uptake. Interpretation super(123)I-FP-CIT SPECT and super(123)I-MIBG myocardial scintigraphy have similar sensitivity for detecting DLB, but the latter appears to be more specific for excluding non-DLB dementias, especially when parkinsonism is the only "core feature" exhibited by the patient. Our data also indicate that the potential confounding effects of diabetes and heart disease on super(123)I-MIBG myocardial scintigraphy results might have been overestimated. Ann Neurol 2016; 80:368-378
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
content type line 23
ObjectType-Feature-2
ISSN:0364-5134
1531-8249
DOI:10.1002/ana.24717